Clinical trials: Onchocerciasis
Lymphatic Filariasis, Soil Transmitted Helminth Infections
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Approximately 3,500 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis endemic areas. The study will be performed in Indonesia in B. timori and W.
- Trial name
- DOLF-Indo (NCT01905423)
- Testing
- Albendazole (annual), Diethylcarbamazine (annual), Albendazole (semiannual)
- Where
- Indonesia
- Volunteers
- 17,108 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
The purpose of this phase 3b study is to determine the safety of a single dose of moxidectin, compared to a single dose of ivermectin, in individuals living in onchocerciasis endemic areas and in individuals living in…
- Trial name
- NCT04311671
- Testing
- Moxidectin, Ivermectin, Albendazole
- Where
- 2 sites in Côte d’Ivoire, Democratic Republic of the Congo
- Volunteers
- 12,979 people, healthy volunteers welcome
- Sponsor
- Medicines Development for Global Health
Healthy Volunteers
First in Man Clinical Trial of Emodepside (BAY 44-4400)
This study will investigate the safety, tolerability, and pharmacokinetics of single ascending doses of emodepside (BAY 44-4400) in healthy male volunteers.
- Trial name
- NCT02661178
- Testing
- emodepside (BAY 44-4400)
- Where
- United Kingdom
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- Drugs for Neglected Diseases
Onchocerciasis
Safety and Efficacy of IDA for Onchocerciasis
This DOLF study will investigate the safety and effectiveness of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with ivermectin to clear or greatly reduce microfilariae from the skin and…
- Trial name
- DOLF IDA/Oncho (NCT04188301)
- Testing
- IVM w/ ALB, Single dose of IDA, Three daily doses of IDA
- Where
- Ghana
- Volunteers
- 154 people
- Sponsor
- Washington University School of Medicine
Onchocerciasis
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
Onchocerciasis is a major public health problem in affected countries that causes disease-induced disability, and overall loss of economic productivity.
- Trial name
- NCT04913610
- Testing
- ABBV-4083, Albendazole
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 153 people
- Sponsor
- AbbVie
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health